中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (1): 5-10.doi: 10.12144/zgmfskin202601005

• 论著 • 上一篇    下一篇

度普利尤单抗与阿布昔替尼治疗特应性皮炎疗效及安全性比较Meta分析

毕志霞,韩金斗   

  1. 山西医科大学附属太原市中心医院皮肤科，山西太原，030009
  • 出版日期:2026-01-15 发布日期:2026-01-15

Dupilumab versus abrocitinib in the treatment of atopic dermatitis: a meta-analysis of efficacy and safety

BI Zhixia, HAN Jindou   

  1. Dermatology Department of Taiyuan Central Hospital Affiliated to Shanxi Medical University, Taiyuan 030009, China
  • Online:2026-01-15 Published:2026-01-15

PDF (PC)

9

摘要： 目的：比较度普利尤单抗与阿布昔替尼治疗特应性皮炎的临床疗效和安全性。方法：检索Pubmed、Web of Science、中国知网（CNKI）、万方等数据库，收集建库至2025年4月发表的使用度普利尤单抗或阿布昔替尼治疗特应性皮炎，并以安慰剂作为对照的所有随机对照研究。以研究对象总体评分（IGA）、湿疹面积及严重度指数（EASI）、瘙痒数字评分量表（PP-NRS）作为评价指标进行Meta分析。结果：共纳入4项研究，IGA结果显示阿布昔替尼200 mg分别优于度普利尤300 mg(RR=1.35, 95% CI:1.20~1.52)、阿布昔替尼100 mg(RR=1.40, 95% CI:1.16~1.68)；EASI75结果显示阿布昔替尼200 mg优于度普利尤300 mg(RR=1.13, 95% CI:1.05~1.21)；PP-NRS结果显示阿布昔替尼200 mg优于度普利尤300 mg(RR=1.12, 95% CI:1.02~1.23)优于阿布昔替尼100 mg(RR=0.78, 95% CI:0.65~0.93)；严重不良反应发生率结果显示阿布昔替尼200 mg与度普利尤单抗300 mg(RR=0.92, 95% CI:0.38~2.25)无明显差异。结论：阿布昔替尼在治疗特应性皮炎的临床疗效上优于度普利尤单抗；在安全性上，与度普利尤单抗相当。

关键词: 度普利尤单抗, 阿布昔替尼, 特应性皮炎, Meta分析

Abstract: Objective: To compare the clinical efficacy and safety of dupilumab and abrocitinib in the treatment of atopic dermatitis. Methods: Databases including PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Database were searched. All randomized controlled trials published from the database establishment to April 2025, in which used dupilumab or abrocitinib was used for the treatment of atopic dermatitis with placebo as the control, were collected. A meta-analysis was conducted with the Investigator's Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Pruritus Numerical Rating Scale (PP-NRS) as the evaluation indicators. Results: A total of 4 studies were included. The IGA results showed that abrocitinib 200 mg was superior to dupilumab 300 mg (RR=1.35, 95% CI:1.20-1.52) and abrocitinib 100 mg (RR=1.40, 95% CI:1.16-1.68), respectively. The EASI75 results showed that abrocitinib 200 mg was superior to dupilumab 300 mg (RR=1.13, 95% CI:1.05-1.21). The PP-NRS results showed that abrocitinib 200 mg was superior to dupilumab 300 mg (RR=1.12, 95% CI:1.02-1.23) and superior to abrocitinib 100 mg (RR=0.78, 95% CI:0.65-0.93). The results of the incidence of serious adverse reactions showed that there was no significant difference between abrocitinib 200 mg and dupilumab 300 mg (RR=0.92, 95% CI:0.38-2.25). Conclusion: Abrocitinib is superior to dupilumab in the clinical efficacy for the treatment of atopic dermatitis, and its safety is comparable to that of dupilumab.

Key words: dupilumab, abrocitinib, atopic dermatitis, meta-analysis